Analysis

Pharma Technology Focus – Issue 64

Pharma Technology Focus – Issue 64

Osteoporosis breakthrough: positive news in a field plagued by bad press

Osteoporosis breakthrough: positive news in a field plagued by bad press

Zika virus: an unlikely new anti-cancer candidate

Zika virus: an unlikely new anti-cancer candidate

Betting big on Gamma Delta T Cells

Betting big on Gamma Delta T Cells

Cystic fibrosis: searching for a breakthrough

Cystic fibrosis: searching for a breakthrough

Treating mononucleosis: why the mystery?

Treating mononucleosis: why the mystery?

Reforming paediatric cancer trials in Europe

Reforming paediatric cancer trials in Europe

Immuno-oncology: where to go in a packed field

Immuno-oncology: where to go in a packed field

Pharma Technology Focus – Issue 60

Pharma Technology Focus – Issue 60

Could a temperature-resistant vaccine spell the end for rabies and yellow fever?

Could a temperature-resistant vaccine spell the end for rabies and yellow fever?

Crowdfunding for cancer therapy

Crowdfunding for cancer therapy

Alzheimer’s drugs: will 2017 bring better news?

Alzheimer’s drugs: will 2017 bring better news?

Illuminating drug discovery by mapping all known drugs

Illuminating drug discovery by mapping all known drugs

How an Alzheimer’s drug turned tooth regenerator could unlock regenerative medicine

How an Alzheimer’s drug turned tooth regenerator could unlock regenerative medicine

Nigeria’s HIV ‘breakthrough’: separating truth from hope

Nigeria’s HIV ‘breakthrough’: separating truth from hope

A peptide to prevent pre-diabetes

A peptide to prevent pre-diabetes

Pharma Technology Focus – Issue 56

Pharma Technology Focus – Issue 56

Why the UK NHS needs clinical research

Why the UK NHS needs clinical research

After the cure: addressing side effects in childhood cancer patients

After the cure: addressing side effects in childhood cancer patients

Pharma Technology Focus – Issue 54

Pharma Technology Focus – Issue 54

Debating the value of targeted lung cancer treatments

Debating the value of targeted lung cancer treatments
cachename:Featurescachekey:rd-137342983_-144940029_rd-1665407042_727740091_rd-488908060_1460672566_ap1460672566_727740091_1970823743